A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Subscribe To Our Newsletter & Stay Updated
